Asunto(s)
Cefalosporinas/farmacocinética , Otitis Media con Derrame/tratamiento farmacológico , Enfermedad Aguda , Adolescente , Cefalosporinas/análisis , Cefalosporinas/uso terapéutico , Niño , Preescolar , Humanos , Lactante , Pruebas de Sensibilidad Microbiana , Otitis Media con Derrame/metabolismo , CefprozilRESUMEN
Four patients had serum sickness-like reactions during treatment with cefprozil, a new cephalosporin. Two patients had had previous mild reactions associated with cephalosporin therapy. It remains uncertain whether cefprozil-associated serum sickness-like reaction represents a unique or a class-related adverse drug reaction.
Asunto(s)
Cefalosporinas/efectos adversos , Enfermedad del Suero/inducido químicamente , Adulto , Bronquitis/tratamiento farmacológico , Niño , Preescolar , Femenino , Humanos , Masculino , Otitis Media/tratamiento farmacológico , Sinusitis/tratamiento farmacológico , CefprozilAsunto(s)
Infecciones Bacterianas/tratamiento farmacológico , Cefaclor/uso terapéutico , Cefalosporinas/uso terapéutico , Enfermedades Cutáneas Infecciosas/tratamiento farmacológico , Niño , Preescolar , Femenino , Humanos , Masculino , Estudios Prospectivos , Infecciones Estafilocócicas/tratamiento farmacológico , Infecciones Estreptocócicas/tratamiento farmacológico , Streptococcus pyogenes , CefprozilRESUMEN
BMY-28100 is a new orally absorbed cephalosporin whose in vitro activity was compared with that of cefaclor. BMY-28100 was more active against Staphylococcus aureus and Haemophilus influenzae than was cefaclor. In addition, there was only a small rise in MIC50 and MIC90 values for BMY-28100 when the inoculum size was increased 100- or 10,000-fold. In contrast, MIC50 and MIC90 values increased significantly for cefaclor with similar increases in inoculum size. These data suggest that BMY-28100 may be a promising agent to test for oral administration in infections caused by S. aureus and H. influenzae.